Suggested targets for VHL-related cancers include targets of the HIF pathway, such as VEGF. Inhibitors of VEGF receptor sorafenib, sunitinib, pazopanib, and recently axitinib have been approved by the FDA.[1] The mTOR inhibitor rapamycin[15] analogs everolimus and temsirolimus or VEGF monoclonal antibody bevacizumab may also be an option.